Table 1 Overall survival in subgroups
Patients (n) | All patients | Patients with CR or PR | Non-responders | HR (95% CI); p value* |
|---|---|---|---|---|
N = 134 | N = 39 | N = 95 | ||
Median (95% CI) | ||||
All patients | NR (29.7, NR) | 4.9 (4.1, 7.0) | < 0.0001 | |
Age | ||||
< 70 (n = 74) | 11.1 (5.4, 28.0) | NR (NR, NR) | 4.9 (3.1, 7.0) | 0.0771 (0.0235,0.2527) < 0.0001 |
≥ 70 (n = 60) | 7.8 (6.1, 13.7) | 29.7 (9.1, NR) | 4.6 (4.1, 12.2) | 0.1912 (0.073,0.5003) 0.0002 |
Region | ||||
North America (n = 20) | 7.6 (4.8, 32.3) | 29.7 (9.0, 29.7) | 4.8 (1.6, 32.3) | 0.2775 (0.0744,1.0356) 0.0430 |
Western Europe and Australia (n = 91) | 10.9 (6.6, 15.5) | NR (NR, NR) | 4.6 (3.0, 7.8) | 0.0994 (0.0392,0.2524) < 0.0001 |
Central and Eastern Europe and India (n = 23) | 6.2 (5.2, NR) | NR (6.2, NR) | 5.4(3.1, NR) | 0.2248 (0.028,1.8032) 0.1241 |
Baseline prognosis | ||||
Very good (R-IPI = 0) or good (R-IPI = 1,2) (n = 69) | 15.1 (10.9, NR) | NR (29.7, NR) | 7.0 (5.2, 15.1) | 0.1511 (0.0613,0.3724) < 0.0001 |
Poor (R-IPI = 3, 4, 5) (n = 58) | 4.6 (3.0, 9.0) | NR (9.0, NR) | 4.1 (2.5, 5.1) | 0.2176 (0.0667,0.7099) 0.0056 |
Number of prior systemic treatment regimens | ||||
2 (n = 79) | 9.1 (5.4, 15.1) | NR (NR, NR) | 4.6 (3.0, 11.1) | 0.131 (0.0509,0.3372) < 0.0001 |
> 2 (n = 55) | 8.2 (5.1, 29.7) | 29.7 (29.7, NR) | 4.9 (3.9, 7.6) | 0.1389 (0.0483,0.3994) < 0.0001 |